[Monoclonal antibodies for the treatment of multiple sclerosis].
Until the mid 1990s, with the appearance of interferon beta and glatiramer acetate, there was no treatment for multiple sclerosis (MS). However, due to their moderate therapeutic potential in some patients, a broad search was continued to find new and more effective treatment strategies, largely concentrated on monoclonal antibodies (MOAB). Natalizumab, the first MOAB for the treatment of MS, was approved at the end of 2004, representing a major advance in the field of neuroimmunology. Today, there is broad experience with natalizumab and other MOAB (alemtuzumab, daclizumab, rituximab, ocrelizumab, ofatumumab and anti-lingo-1) that are pending commercialization or are under phase II or III of development with promising results. The present review analyzes the efficacy and safety results of all these drugs.
Unidad de Enfermedades Desmielinizantes, Hospital Clínico San Carlos, Madrid, España.
Victoria Galán
VG
Sánchez-Seco
Unidad de Enfermedades Desmielinizantes, Hospital Clínico San Carlos, Madrid, España.
Ignacio
I
Casanova Peño
Unidad de Enfermedades Desmielinizantes, Hospital Clínico San Carlos, Madrid, España. Electronic address: rafaelarroyo09@gmail.com.
Rafael
R
Arroyo González
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000077561:Daclizumab; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D000074323:Alemtuzumab; D000077561:Daclizumab
Alemtuzumab; BIIB033; Daclizumab; Esclerosis múltiple; Multiple sclerosis; Natalizumab; Ocrelizumab; Ofatumumab; Rituximab